Krebs, M. G., Cho, B. C., Hiret, S., Han, J.-Y., Lee, K. H., Llácer Pérez, C., De Braud, F., Haura, E. B., Sanborn, R. E., Yang, J. C.-H., Shu, C. A., Goto, K., Nishio, M., Zhao, J., Wang, Z., Tomasini, P., Felip, E., Goldman, J. W., Ou, S.-H. I., … Leighl, N. B. (2025). Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2025.05.012

Besse, B., Goto, K., Wang, Y., Lee, S.-H., Marmarelis, M. E., Ohe, Y., Caro, R. B., Kim, D.-W., Lee, J.-S., Cousin, S., Ichihara, E., Li, Y., Paz-Ares, L., Ono, A., Sanborn, R. E., Watanabe, N., Jose de Miguel, M., Helissey, C., Shu, C. A., … Cho, B. C. (2025). Amivantamab Plus Lazertinib in Patients With EGFR-mutant Non-small Cell Lung Cancer (NSCLC) After Progression on Osimertinib and Platinum-based Chemotherapy: Results From CHRYSALIS-2 Cohort A. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2024.12.029

Chou, T.-Y., Dacic, S., Wistuba, I., Beasley, M. B., Berezowska, S., Chang, Y.-C., Chung, J.-H., Connolly, C., Han, Y., Hirsch, F. R., Hwang, D. M., Janowczyk, A., Joubert, P., Kerr, K. M., Lin, D., Minami, Y., Mino-Kenudson, M., Nicholson, A. G., Papotti, M., … Cooper, W. A. (2024). Differentiating separate primary lung adenocarcinomas from intrapulmonary metastases with emphasis on pathological and molecular considerations: Recommendations from the IASLC Pathology Committee. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2024.11.016

Wang, K., Du, R., Myall, N. J., Lewis, W. E., Uy, N., Hong, L., Skoulidis, F., Byers, L. A., Tsao, A., Cascone, T., Pozadzides, J., Tu, J., Negrao, M. V., Gibbons, D. L., Park, K., Rinsurongkawong, W., Lee, J. J., Gandara, D., Behl, D., … Le, X. (2024). Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 19(3), 500–506. https://doi.org/10.1016/j.jtho.2023.11.020

Leighl, N., Cho, B. C., Hiret, S., Han, J.-Y., Lee, K. H., Llacer Perez, C., Krebs, M. G., De Braud, F., Haura, E., Sanborn, R. E., Yang, J. C.-H., Shu, C. A., Goto, K., Nishio, M., Zhao, J., Wang, Z., Tomasini, P., Felip, E., Goldman, J. W., … Spira, A. I. (2023). OA21.04 Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study. Journal of Thoracic Oncology, 18(11), S93–S94. https://doi.org/10.1016/j.jtho.2023.09.105

Lee, J. M., Toloza, E. M., Pass, H. I., Johnson, B. E., Heymach, J. V., Sholl, L., Saqi, A., Travis, W. D., Wistuba, I., Lin, J., Kris, M. G., Spira, A. I., Shu, C. A., Saltos, A. N., Ding, B., Schulze, K., Zhu, Q., Ngiam, C., Bara, I., & Chaft, J. E. (2023). P2.01-06 NAUTIKA1 Study: Preliminary Efficacy and Safety Data with Neoadjuvant Alectinib in Patients with Stage IB-III ALK+ NSCLC. Journal of Thoracic Oncology, 18(11), S297–S298. https://doi.org/10.1016/j.jtho.2023.09.511

Dacic, S., Travis, W., Redman, M., Saqi, A., Cooper, W. A., Borczuk, A., Chung, J.-H., Glass, C., Lopez, J. M., Roden, A. C., Sholl, L., Weissferdt, A., Posadas, J., Walker, A., Zhu, H., Wijeratne, M. T., Connolly, C., Wynes, M., Bota-Rabassedas, N., … Wistuba, I. (2023). International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. Journal of Thoracic Oncology, 18(10), 1290–1302. https://doi.org/10.1016/j.jtho.2023.07.017

Dercle, L., Fronheiser, M., Rizvi, N. A., Hellmann, M. D., Maier, S., Hayes, W., Yang, H., Guo, P., Fojo, T., Schwartz, L. H., Zhao, B., & Leung, D. K. (2023). Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC. Journal of Thoracic Oncology, 18(5), 587–598. https://doi.org/10.1016/j.jtho.2022.12.019

Kim, D.-W., Kim, S.-W., Camidge, D. R., Shu, C. A., Marrone, K. A., Le, X., Blakely, C. M., Park, K., Chang, G.-C., Patel, S. P., Kar, G., Cooper, Z. A., Samadani, R., Pluta, M., Kumar, R., & Ramalingam, S. (2023). CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report. Journal of Thoracic Oncology, 18(5), 650–656. https://doi.org/10.1016/j.jtho.2022.12.021

de Castro, G., Rizvi, N. A., Schmid, P., Syrigos, K., Martin, C., Yamamoto, N., Cheng, Y., Moiseyenko, V., Summers, Y., Vynnychenko, I., Lee, S. Y., Bryl, M., Zer, A., Erman, M., Timcheva, C., Raja, R., Naicker, K., Scheuring, U., Walker, J., … Mok, T. (2023). NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC. Journal of Thoracic Oncology, 18(1), 106–119. https://doi.org/10.1016/j.jtho.2022.09.223

Dercle, L., Gomez, D., Zhao, B., Kelly, K., Herbst, R. S., Redman, M. W., Gandara, D. R., & Schwartz, L. H. (2022). P2.12-03 External Validation of a Novel CT-Based Prognostic Radiomic Signature in Patients with Metastatic NSCLC in SWOG S0819 Phase III Randomized Trial. Journal of Thoracic Oncology, 17(9), S152. https://doi.org/10.1016/j.jtho.2022.07.251

Bondarenko, I., Sezer, A., Kilickap, S., Gümüş, M., Özgüroğlu, M., Gogishvili, M., Turk, H. M., Cicin, I., Bentsion, D., Gladkov, O., Clingan, P., Sriuranpong, V., Rizvi, N., Mcginniss, J., Pouliot, J., Lee, S., Seebach, F., Lowy, I., Gullo, G., & Rietschel, P. (2021). FP04.03 Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1. Journal of Thoracic Oncology, 16(10), S951. https://doi.org/10.1016/j.jtho.2021.08.217

Spigel, D. R., Akerley, W., Evangelist, M., Johnson, M., Levy, B., Owonikoko, T., Paik, P., Papagiannakopoulos, T., Reckamp, K., Akella, L., Holland, S., Jenkins, Y., Kuriakose, E., & Rizvi, N. (2021). P47.07 KEAPSAKE Study of Telaglenastat vs Placebo Plus Standard-of-Care in 1L KEAP1/NRF2-Mutated Non-Squamous Metastatic NSCLC. Journal of Thoracic Oncology, 16(10), S1099. https://doi.org/10.1016/j.jtho.2021.08.500

Nagasaka, M., Goto, K., Gomez, J., Hida, T., Shu, C., Lee, C. K., Park, K., Cho, B. C., Lee, J., Ou, S., Bestvina, C., Natale, R., Haddish-Berhane, N., Bhattacharya, A., Verheijen, R., Agrawal, T., Knoblauch, R., & Govindan, R. (2021). P50.04 Amivantamab in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 16(10), S1116. https://doi.org/10.1016/j.jtho.2021.08.532